Clinical Trial Update: Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating toripalimab plus lenvatinib as second-line treatment for advanced biliary tract cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• toripalimab + lenvatinib

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Advanced Biliary Tract Cancer | Phase 2 | Status: UNKNOWN